{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:33:12Z","timestamp":1790249592610,"version":"4.1.0"},"reference-count":82,"publisher":"The Korean Association for the Study of the Liver","issue":"3","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["CMH"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease, is the most common liver disease in Western countries and has emerged as the leading indication for liver transplantation. Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage, carries a high risk of progression to liver fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. Until recently, lifestyle intervention remained the mainstay of MASH management, with no pharmacological treatments specifically approved. However, advances in understanding its pathophysiological mechanisms have fueled numerous clinical trials, culminating in the Food and Drug Administration\u2019s (FDA) approval of resmetirom as the first treatment for MASH in 2024. Additionally, many investigational drugs are nearing FDA approval or progressing through late-stage clinical trials. This review examines the current therapeutic landscape, highlights strategies for identifying patients suitable for liver-directed therapies in real-world settings, and discusses the challenges that remain.<\/jats:p>","DOI":"10.3350\/cmh.2025.0083","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:11:52Z","timestamp":1743552712000},"page":"753-770","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment"],"prefix":"10.3350","volume":"31","author":[{"given":"Hee Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-9705","authenticated-orcid":true,"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","first-page":"124","volume-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","author":"Williams","year":"2011"},{"key":"ref2","first-page":"1966","volume-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000004"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0088-6"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.75.10.721"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i47.8263"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000539371"},{"key":"ref8","volume-title":"FDA Approves first treatment for patients with liver scarring due to fatty liver disease"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/jci129187"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25539"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1439-8"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101777"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-024-01267-9"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa099"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0067"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"ref19","volume-title":"Projection of the clinical burden of NAFLD in US adults from 2020-2050: a modeling study","author":"Le"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21890"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.006"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000323"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31296"},{"key":"ref24","first-page":"497","volume-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","author":"Harrison","year":"2024"},{"key":"ref25","first-page":"5","volume-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","author":"Nauck","year":"2021"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00213-0"},{"key":"ref27","volume-title":"Phase 3 ESSENCE trial: semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)","author":"Newsome"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13955"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17925"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330962"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2401943"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2401755"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01443-4"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00070-5"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0209-6"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00272-8"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2304286"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0386-0"},{"key":"ref40","volume-title":""},{"key":"ref41","volume-title":""},{"key":"ref42","first-page":"S1","volume-title":"Once-monthly efimosfermin alfa (BOS-580) in metabolic dysufnction-associated steatoheatitis with F2\/F3 fibrosis: results from a 24 week, randomized, double-blind, placebo-controlled, phase 2 trial [Abstract]","author":"Noureddin","year":"2024"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.025"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062061"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2036205"},{"key":"ref46","first-page":"15661","volume-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","author":"O\u2019Farrell","year":"2022"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00246-2"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.02.004"},{"key":"ref49","first-page":"E44","volume-title":"Icosabutate in NASH\/MASH with fibrosis: results from a randomised, multicentre, double-blind, placebo controlled, phase 2b trial (Icona) [Abstract]","author":"Harrison","year":"2024"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02242-6"},{"key":"ref51","volume-title":""},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.027"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.12.015"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12289"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.008"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.003"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001112"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00066-3"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.08.036"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.045"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(24)04014-9"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.1447"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.021"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.014"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00017-1"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.008"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.031"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.029"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24069"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2026702"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00370-2"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2393952"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.03.004"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.046"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.025"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000860"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01084-2"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.02.022"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00068-7"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0438"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2025-0083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2025.0083","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2025-0083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:48:19Z","timestamp":1765259299000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2025.0083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2025.0083","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-02","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}